Patients with extramedullary leukemia were identified over 10 years (January 2003 to September 2019). Clinicopathological,genetic-molecular features were identified and survival outcomes were studied and analyzed.
We retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between January 2003 till September 2019 from King Hussein cancer center(KHCC) electronic medical records. All potential prognostic factors were identified and compared with worldwide data published previously. Treatment and survival outcomes were studies and analyzed. Primary endpoint : Overall survival (OS). Secondary endpoint : * Progression Free Survival (PFS). * incidence of extramedullary leukemia.
Study Type
OBSERVATIONAL
Enrollment
32
chart review, analysis and reporting outcomes
King Hussein Cancer Center
Amman, Jordan
Overall survival (OS),
To calculate the median and estimated 4-year overall survival
Time frame: "4 year, year 4"
Progression-Free Survival
To calculate the median and estimated 4-year PFS
Time frame: "4 year, year 4"
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.